Clinical trials: Cultural Safety
Influenza A Subtype H5N1 Infection
Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.
The purpose of this study is to test the recombinant vaccine for safety and immunogenicity in healthy adults volunteers. Single dose, intranasally administered vaccine using an adenovirus-recombinant vector has provided a safe…
- Trial name
- NCT00755703
- Testing
- Pandemic Influenza Vaccine
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
Influenza, Human, Infections
Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults
This Phase 2, randomized, observer-blind clinical study is evaluating 3 different priming and booster regimens with MF59-adjuvanted H5N8 and/or H5N6 cell culture-derived influenza vaccine (aH5N8c; aH5N6c).
- Conditions
- Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases
- Trial name
- NCT05874713
- Testing
- aH5N8c on Day 1, aH5N6c on Day 1, aH5N8c on Day 22
- Where
- 9 sites in United States
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza, Human
Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children Aged 6~35 Months
This study is a multi-center, randomized, double-blind Phase III Clinical trial. The purpose of this study is to assess the immunogenicity and safety of the quadrivalent cell culture-derived influenza vaccine compare to the…
- Trial name
- NCT03020628
- Testing
- NBP607-QIV, NBP607-TIV
- Where
- 12 sites in South Korea
- Volunteers
- 171 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Influenza, Fever
Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age
Evaluate safety and tolerability of TIVa or TIVb vaccine in healthy children and adolescents 4 to 17 years of age.
- Trial name
- NCT01857206
- Testing
- Mammalian cell based flu vaccine, Egg based flu vaccine
- Where
- 34 sites in United States, Australia and 3 more
- Volunteers
- 2,055 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older Against Culture-confirmed Influenza
To demonstrate that the efficacy over a defined surveillance period against culture-confirmed influenza-illness caused by community-acquired subtypes antigenically similar to those contained in the vaccine, in adults aged at…
- Trial name
- FluMist (NCT00192413)
- Testing
- Cold-adapted influenza vaccine trivalent (CAIV-T), Trivalent Inactivated Vaccine (TIV)
- Where
- 4 sites in South Africa
- Volunteers
- 3,009 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and Elderly
The present study aims to evaluate the safety and immunogenicity of the new influenza subunit vaccine produced in Madin Darby Canine Kidney (MDCK) cells in healthy adult and elderly subjects.
- Trial name
- NCT00492063
- Testing
- Cell culture-derived trivalent subunit influenza vaccine (cTIV), Egg-derived trivalent subunit influenza vaccine (TIV)
- Where
- 5 sites in Poland
- Volunteers
- 2,654 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects
All participants received a single dose of their assigned vaccine on Day 0. They were followed up for immunogenicity and safety through Day 21 post-vaccination. Serious adverse events were collected for 6 months post-vaccination.
- Trial name
- NCT02467842
- Testing
- NBP607-QIV, NBP607-Y, NBP607-V
- Volunteers
- 1,503 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Influenza
Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old
This study will assess safety and immunogenicity of GSK Biologicals' H5N1 flu candidate vaccines GSK2590066A and GSK2340273A in healthy adults 18 - 49 years old.
- Trial name
- NCT01236040
- Testing
- GSK Biologicals' investigational vaccine GSK2590066A, GSK Biologicals' investigational vaccine GSK2592984A, GSK Biologicals' investigational vaccine GSK2340274A
- Where
- 4 sites in United States
- Volunteers
- 521 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix
The purpose of the study is to compare the safety of \& immune response to a single dose of GSK Biologicals' cell-culture based influenza vaccine 138842A with that of a US licensed, egg-based trivalent influenza vaccine [Fluarix]…
- Trial name
- NCT00693706
- Testing
- Trivalent influenza vaccine GSK 138842A, Fluarix
- Where
- 2 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pandemic H5N1 Influenza
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
Evaluate Safety, Tolerability and Immune response of adjuvanted H5N1 cell culture derived influenza vaccine in children.
- Trial name
- NCT01776554
- Testing
- Adjuvanted H5N1 pandemic influenza vaccine
- Where
- 12 sites in United States, Thailand
- Volunteers
- 662 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Avian Influenza
A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age
This Phase 3 study evaluates the safety, immunogenicity and lot-to lot consistency of 3 lots of aH5N1c vaccine for pandemic avian influenza, in approximately 2394 healthy adults ≥18 years of age receiving the vaccine and 797…
- Trial name
- NCT02839330
- Testing
- aH5N1c
- Where
- 26 sites in United States
- Volunteers
- 3,196 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents
The present study is the first study designed to evaluate safety, tolerability and immunogenicity of the cell culture-derived influenza vaccine in healthy children and adolescents aged 3 to 17 years.
- Trial name
- NCT00645411
- Testing
- Cell culture-derived influenza subunit vaccine (cTIV), Egg derived influenza subunit vaccine (eTIV)
- Where
- 60 sites in United States, Croatia and 5 more
- Volunteers
- 3,604 people, healthy volunteers welcome
- Sponsor
- Novartis
Seasonal Influenza, Vaccine
Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions
Evaluation of the safety of Trivalent Subunit Influenza Vaccine Produced either in Mammalian Cell Culture or in embryonated Hen Eggs in subjects 18 years of age and above with and without underlying medical conditions and…
- Trial name
- NCT00560066
- Testing
- Cell-derived influenza vaccine, Egg-derived influenza vaccine
- Where
- 15 sites in Germany
- Volunteers
- 1,398 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Prosthetic Joint Infection, Bacterial Infections
Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections
This study will test the feasibility of a regimen of intraoperative (IO) and intravenous (IV) PhageBank™ bacteriophage therapy in conjunction with a DAIR procedure to cure chronic prosthetic joint infection (PJI) without…
- Trial name
- ACTIVE1 (NCT05269121)
- Testing
- Phage Therapy
- Sponsor
- Adaptive Phage Therapeutics, Inc.
Seasonal Influenza Vaccine
Safety and Immunogenicity of Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Using the Strain Composition 2007/2008
Annual trial for registration of sub-unit influenza vaccine produced in mammalian cell culture, using the strain composition 2007/2008, when administered to adult and elderly subjects
- Trial name
- NCT00511914
- Testing
- cTIV
- Where
- 2 sites in Germany
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Multidrug-resistant Tuberculosis
Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis
The purpose of this trial is to determine whether delamanid is effective in the treatment of multidrug-resistant tuberculosis (MDR TB) in combination with other MDR TB medications during 6 months of treatment.
- Trial name
- NCT01424670
- Testing
- Delamanid + OBR
- Where
- 17 sites in Estonia, Latvia and 5 more
- Volunteers
- 511 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Tuberculosis, Pulmonary, Tuberculosis, Multidrug Resistant
A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)
This is a clinical trial to evaluate the safety and efficacy of OPC-67683 in the treatment of multidrug resistant tuberculosis (MDR TB) for 56 days.
- Conditions
- Tuberculosis, Pulmonary, Tuberculosis, Multidrug Resistant, Extensively Drug-Resistant Tuberculosis
- Trial name
- NCT00685360
- Testing
- Delamanid, Optimized Background Regimen (OBR)
- Where
- 17 sites in United States, China and 7 more
- Volunteers
- 481 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.